Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Characterization of Cerebral Amyloid Deposition With 18F-Flutemetamol PET and of Glucose Metabolism With 18F-FDG PET in Individuals Enrolled in the ALFA Project.

Next Previous
Trial Profile

Characterization of Cerebral Amyloid Deposition With 18F-Flutemetamol PET and of Glucose Metabolism With 18F-FDG PET in Individuals Enrolled in the ALFA Project.

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fludeoxyglucose F-18 (Primary) ; Flutemetamol-F-18 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics

Most Recent Events

  • 31 May 2025 Planned number of patients changed from 440 to 570.
  • 31 May 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2027.
  • 31 May 2025 Planned primary completion date changed from 1 Mar 2019 to 31 Dec 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top